Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 2797 

Bldg., 725 17th St. NW, Rm. 10235, 

Washington, DC 20503, Attn: OMB Desk 

Officer for ACL. 

FOR FURTHER INFORMATION CONTACT: 

Peter Nye, Administration for 

Community Living, Washington, DC 

20201, (202) 795–7606 or 

OILPPRAComments@acl.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, ACL 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. The 

Administration for Community Living 

(ACL) is requesting approval to collect 

data for information collection 

requirements related to Centers for 

Independent Living Program 

Performance Report (CIL PPR) (0985– 

0061). In the context of ACL, IL 

programs are supported through funding 

authorized by the Rehabilitation Act of 

1973, as amended (The Act). Title VII, 

chapter 1 of the Act states the current 

purpose of the program is to ‘‘promote 

a philosophy of independent living 

including a philosophy of consumer 

control, peer support, self-help, selfdetermination, equal access, and 

individual and system advocacy, in 

order to maximize the leadership, 

empowerment, independence, and 

productivity of individuals with 

disabilities, and the integration and full 

inclusion of individuals with 

disabilities into the mainstream of 

American society.’’ 

The CIL PPR is submitted annually by 

all CILs receiving IL Part C funds. The 

PPRs are used by ACL to assess 

grantees’ compliance with title VII of 

the Act, and with 45 CFR 1329 of the 

Code of Federal Regulations and with 

applicable provisions of the HHS 

Regulations at 45 CFR part 75. The PPR 

serves as the primary basis for ACL’s 

monitoring activities in fulfillment of its 

responsibilities under sections 706 and 

722 of the Act. The PPR also enables 

ACL to track performance outcomes and 

efficiency measures of the CIL programs 

with respect to the annual and longterm performance targets established in 

compliance with GPRA. The PPR is also 

used by ACL to design CIL and 

Statewide Independent Living Council 

training and technical assistance 

programs authorized by section 711A 

and section 721 of the Act. 

The CARES Act PPR is submitted 

annually by all CILs receiving CARES 

Act funds. The CARES Act requires ACL 

grantees that receive CARES Act 

funding to report quarterly, to ACL and 

to the Pandemic Response 

Accountability Committee, ‘‘the total 

amount of large covered funds that the 

grantee received from ACL; the amount 

of large covered funds received that 

were expended or obligated for each 

project or activity; a detailed list of all 

projects or activities for which large 

covered funds were expended or 

obligated, including the name of the 

project or activity; a description . . . ; 

and the estimated number of jobs 

created or retained by the project or 

activity, where applicable; and detailed 

information on any subcontracts or 

Subgrants . . .’’ Coronavirus Aid, 

Relief, and Economic Security Act, 

Public Law 116–136, H.R. 748 15011(a– 

b), 116th Cong. (2020). 

The current version of the CIL PPR 

(that includes the CARES Act PPR) that 

OILP is requesting an extension for was 

approved by OMB; the approval was 

extended and will expire on January 31, 

2022. 

Comments in Response to the 60-Day 

Federal Register Notice 

A notice was published in the Federal 

Register on August 9, 2021 (Vol. 86, 

Number 2021–16752; pp. 43549–43550). 

We received no comments during the 

60-day comment period. 

Estimated Program Burden: ACL 

estimates the burden of this collection 

of information as follows: The twohundred ninety Part C CILs will 

complete 353 CIL PPRs annually, and it 

will take an estimated 35 hours per CIL 

per CIL PPR for an estimated total of 

12,355 hours. Two-hundred ninety CILs 

will each complete CARES Act PPRs, 

and it will take an estimated forty-six 

hours per CIL per CARES Act PPR. The 

two-hundred ninety Part C CILs will 

take an estimated 13,340 hours to 

complete CARES Act PPRs. The twohundred ninety Part C CILs will spend 

an estimated 25,695 hours completing 

CIL PPRs and CARES Act PPRs. These 

burden estimates are based on ACL’s 

estimate of the average time required to 

collect the information collected in the 

PPR and feedback from CILs on the time 

needed to complete the PPR. 

Respondent Data collection activity Number of 

respondents 

Responses 

per 

respondent 

Hours per 

response 

Total Annual 

burden hours 

CILs ................................................... CIL PPR ........................................... 353 1 35 12,355 

CILs ................................................... CARES Act PPR .............................. 290 1 46 13,340 

CILs ................................................... Total .......................................... ........................ 2 81 25,695 

Dated: January 12, 2022. 

Alison Barkoff, 

Principal Deputy Administrator. 

[FR Doc. 2022–00892 Filed 1–18–22; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2013–N–0297] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Prevention of 

Salmonella Enteritidis in Shell Eggs 

During Production; Recordkeeping and 

Registration Provisions 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on the information 

collection provisions of FDA’s 

recordkeeping and registration 

requirements for shell egg producers. 


jspears on DSK121TN23PROD with NOTICES1
2798 Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 

DATES: Submit either electronic or 

written comments on the collection of 

information by March 21, 2022. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before March 21, 

2022. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of March 21, 2022. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2013–N–0297 for ‘‘Agency Information 

Collection Activities; Proposed 

Collection; Comment Request; 

Prevention of Salmonella Enteritidis in 

Shell Eggs During Production; 

Recordkeeping and Registration 

Provisions.’’ Received comments, those 

filed in a timely manner (see 

ADDRESSES), will be placed in the docket 

and, except for those submitted as 

‘‘Confidential Submissions,’’ publicly 

viewable at https://www.regulations.gov 

or at the Dockets Management Staff 

between 9 a.m. and 4 p.m., Monday 

through Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

FOR FURTHER INFORMATION CONTACT: 

Rachel Showalter, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 240–994–7399, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3521), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes Agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

Agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Prevention of Salmonella Enteritidis in 

Shell Eggs During Production— 

Recordkeeping and Registration 

Provisions—21 CFR 118.10 and 118.11 

OMB Control Number 0910–0660— 

Extension 

This information collection supports 

Agency regulations in part 118 (21 CFR 

part 118), Production, Storage, and 

Transportation of Shell Eggs, and Form 

FDA 3733, Shell Egg Producer 

Registration Form. The Public Health 

Service Act (PHS Act) (42 U.S.C. 264) 

authorizes the Secretary of Health and 

Human Services to make and enforce 

such regulations as ‘‘are necessary to 

prevent the introduction, transmission, 

or spread of communicable diseases 

from foreign countries into the States 

. . . or from one State . . . into any 

other State’’ (section 361(a) of the PHS 

Act (42 U.S.C. 264(a))). This authority 

has been delegated to the Commissioner 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 2799 

of Food and Drugs. Under section 

402(a)(4) of the Federal Food, Drug, and 

Cosmetic Act (FD&C Act) (21 U.S.C. 

342(a)(4)), a food is adulterated if it is 

prepared, packed, or held under 

insanitary conditions whereby it may 

have been contaminated with filth or 

rendered injurious to health. Under 

section 701(a) of the FD&C Act (21 

U.S.C. 371(a)), FDA is authorized to 

issue regulations for the efficient 

enforcement of the FD&C Act. 

Under part 118, shell egg producers 

are required to implement measures to 

prevent Salmonella Enteritidis (SE) from 

contaminating eggs on the farm and 

from further growth during storage and 

transportation. Shell egg producers also 

are required to maintain records 

concerning their compliance with part 

118 and to register with FDA. As 

described in more detail about each 

information collection provision of part 

118, each farm site with 3,000 or more 

egg laying hens that sells raw shell eggs 

to the table egg market, other than 

directly to the consumer, must 

refrigerate, register, and keep certain 

records. Farms that do not send all of 

their eggs to treatment are also required 

to have an SE prevention plan and to 

test for SE. 

Section 118.10 of FDA’s regulations 

requires recordkeeping for all measures 

the farm takes to prevent SE in its 

flocks. Since many existing farms 

participate in voluntary egg quality 

assurance programs, those respondents 

may not have to collect any additional 

information. Records are maintained on 

file at each farm site and examined there 

periodically by FDA inspectors. 

Section 118.10 also requires each farm 

site with 3,000 or more egg laying hens 

that sells raw shell eggs to the table egg 

market, other than directly to the 

consumer, and does not have all of the 

shell eggs treated, to design and 

implement an SE prevention plan. 

Section 118.10 requires recordkeeping 

for each of the provisions included in 

the plan and for plan review and 

modifications if corrective actions are 

taken. 

Finally, § 118.11 of FDA’s regulations 

requires that each farm covered by 

§ 118.1(a) register with FDA using Form 

FDA 3733. The term ‘‘Form FDA 3733’’ 

refers to both the paper version of the 

form and the electronic system known 

as the Shell Egg Producer Registration 

Module, which is available at https://

www.access.fda.gov. We strongly 

encourage electronic registration 

because it is faster and more convenient. 

The system can accept electronic 

registrations 24 hours a day, 7 days a 

week. A registering shell egg producer 

receives confirmation of electronic 

registration instantaneously once all the 

required fields on the registration screen 

are completed. However, paper 

registrations will also be accepted. Form 

FDA 3733 is available for download for 

registration by mail, fax or CD–ROM. 

For more information, we invite you to 

visit our website at https://www.fda.gov/ 

food/registration-food-facilities-andother-submissions/shell-egg-producerregistration. 

Recordkeeping and registration are 

necessary for the success of the SE 

prevention measures. Written SE 

prevention plans and records of actions 

taken due to each provision are essential 

for farms to implement SE prevention 

plans effectively. Further, they are 

essential for us to be able to determine 

compliance. Information provided 

under these regulations helps us to 

quickly notify the facilities that might 

be affected by a deliberate or accidental 

contamination of the food supply. In 

addition, data collected through 

registration is used to support our 

enforcement activities. 

Description of Respondents: 

Respondents to this information 

collection include farm sites with 3,000 

or more egg laying hens that sell raw 

eggs to the table egg market, other than 

directly to the consumer. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1

Activity; 21 CFR section Number of 

recordkeepers 2

Number of 

records per 

recordkeeper 

Total annual 

records 

Average 

burden per 

recordkeeping 

Total hours 

Refrigeration Records; § 118.10(a)(3)(iv) ........................................... 2,600 52 135,200 0.5 (30 minutes) ......... 67,600 

Testing, Diversion, and Treatment Records; § 118.10(a)(3)(v) 

through (viii) (positive) 3.

343 52 17,836 0.5 (30 minutes) ......... 8,918 

Egg Testing; § 118.10(a)(3)(vii) .......................................................... 331 7 2,317 8.3 ............................... 19,231 

Environmental Testing; § 118.10(a)(3)(v) 3 ........................................ 6,308 23 145,084 0.25 (15 minutes) ....... 36,271 

Testing, Diversion, and Treatment Records; § 118.10(a)(3)(v) 

through (viii) (negative) 3.

5,965 1 5,965 0.5 (30 minutes) ......... 2,983 

Prevention Plan Review and Modifications; § 118.10(a)(4) ............... 331 1 331 10 ................................ 3,310 

Chick and Pullet Procurement Records; § 118.10(a)(2) .................... 4,731 1 4,731 0.5 (30 minutes) ......... 2,366 

Rodent and Other Pest Control; § 118.10(a)(3)(ii), and Biosecurity 

Records, § 118.10(a)(3)(i).

9,462 52 492,024 0.5 (30 minutes) ......... 246,012 

Prevention Plan Design; § 118.10(a)(1) ............................................. 350 1 350 20 ................................ 7,000 

Cleaning and Disinfection Records; § 118.10(a)(3)(iii) ...................... 331 1 331 0.5 (30 minutes) ......... 166 

Total ............................................................................................ .............................. ........................ ........................ ..................................... 393,857 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

2Some records are kept on a by-farm basis and others are kept on a by-house basis. 

3 Calculations include requirements for pullet and layer houses. 

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN1

Activity; 21 CFR section Form Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

Registrations or Updates; § 118.11 ....................................... FDA 3733 2 ........ 350 1 350 2.3 805 

Cancellations; § 118.11 ......................................................... FDA 3733 .......... 30 1 30 1 30 

Total ............................................................................... ........................... ........................ ........................ ........................ ........................ 835 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

2The term ‘‘Form FDA 3733’’ refers to both the paper version of the form and the electronic system known as the Shell Egg Producer Registration Module, which is 

available at http://www.access.fda.gov per § 118.11(b)(1). 


jspears on DSK121TN23PROD with NOTICES1
2800 Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 

Based on a review of the information 

collection since our last request for 

OMB approval, we have made no 

adjustments to our burden estimate. Our 

estimates for the recordkeeping burden 

and the reporting burden are based on 

our experience with similar 

recordkeeping activities and the number 

of registrations and cancellations 

received in the past 3 years. 

Dated: January 11, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–00863 Filed 1–18–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Heritable Disorders in Newborns and 

Children 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the Public 

Health Service Act and the Federal 

Advisory Committee Act, this notice 

announces that the Advisory Committee 

on Heritable Disorders in Newborns and 

Children (ACHDNC or Committee) has 

scheduled a public meeting to be held 

on Thursday, February 10, 2022, and 

Friday, February 11, 2022. Information 

about the ACHDNC and the agenda for 

this meeting can be found on the 

ACHDNC website at https://

www.hrsa.gov/advisory-committees/ 

heritable-disorders/index.html. 

DATES: Thursday, February 10, 2022, 

from 10:00 a.m.–3:00 p.m. Eastern Time 

(ET) and Friday, February 11, 2022, 

from 10 a.m.–2:30 p.m. ET. 

ADDRESSES: This meeting will be held 

via webinar. While this meeting is open 

to the public, advance registration is 

required. 

Please visit the ACHDNC website for 

information on registration: https://

www.hrsa.gov/advisory-committees/ 

heritable-disorders/index.html. The 

deadline for registration is 12:00 p.m. 

ET on February 9, 2022. Instructions on 

how to access the meeting via webcast 

will be provided upon registration. 

FOR FURTHER INFORMATION CONTACT: 

Alaina Harris, Maternal and Child 

Health Bureau, HRSA, 5600 Fishers 

Lane, Room 18W66, Rockville, 

Maryland 20857; 301–443–0721; or 

ACHDNC@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACHDNC 

provides advice and recommendations 

to the Secretary of Health and Human 

Services (Secretary) on the development 

of newborn screening activities, 

technologies, policies, guidelines, and 

programs for effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders. The ACHDNC 

reviews and reports regularly on 

newborn and childhood screening 

practices, recommends improvements in 

the national newborn and childhood 

screening programs, and fulfills 

requirements stated in the authorizing 

legislation. In addition, ACHDNC’s 

recommendations regarding inclusion of 

additional conditions for screening on 

the Recommended Uniform Screening 

Panel (RUSP), following adoption by the 

Secretary, are evidence-informed 

preventive health services provided for 

in the comprehensive guidelines 

supported by HRSA pursuant to section 

2713 of the Public Health Service Act 

(42 U.S.C. 300gg–13). Under this 

provision, non-grandfathered group 

health plans and health insurance 

issuers offering non-grandfathered 

group or individual health insurance are 

required to provide insurance coverage 

without cost-sharing (a co-payment, coinsurance, or deductible) for preventive 

services for plan years (i.e., policy years) 

beginning on or after the date that is one 

year from the Secretary’s adoption of the 

condition for screening. 

During the February 10–11, 2022 

meeting, ACHDNC will hear from 

experts in the fields of public health, 

medicine, heritable disorders, rare 

disorders, and newborn screening. 

Agenda items include the following: 

(1) Final evidence-based review report 

on the Mucopolysaccharidosis type II 

(MPS II) condition nomination for 

possible inclusion on the RUSP. 

Following this report, the ACHDNC 

expects to vote on whether to 

recommend to the Secretary adding 

MPS II to the RUSP. 

(2) A presentation on phase two of the 

evidence-based review for 

Guanidinoacetate methyltransferase 

(GAMT) deficiency. 

(3) An update on the Krabbe disease 

condition nomination. 

(4) A possible vote on whether to 

move Krabbe disease forward to full 

evidence-based review. 

(5) Overview of ACHDNC consumerfriendly resources. 

(6) A presentation on healthy equity 

in newborn screening. 

The agenda for this meeting includes 

a potential vote which may lead to a 

decision to recommend a nominated 

condition (MPS II) to the RUSP. As 

noted in the agenda items, the 

Committee may hold a vote on whether 

or not to recommend a nominated 

condition (Krabbe disease) to full 

evidence-based review, and will hear 

presentations on the evidence-based 

review for Guanidinoacetate 

methyltransferase deficiency, any of 

which may lead to a recommendation to 

add or not add a condition/conditions to 

the RUSP at a future time. 

Agenda items are subject to change as 

priorities dictate. Information about the 

ACHDNC, including a roster of members 

and past meeting summaries, is also 

available on the ACHDNC website listed 

above. 

Members of the public also will have 

the opportunity to provide comments. 

Public participants providing oral 

comments may submit written 

statements in advance of the scheduled 

meeting. Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Subject to change: Members of the 

public registered to submit oral public 

comments on MPS II are tentatively 

scheduled to provide their statements 

on Thursday, February 10, 2022. 

Members of the public registered to 

provide statements on all other newborn 

screening related topics are tentatively 

scheduled for Friday, February 11, 2022. 

Requests to provide a written statement 

or make oral comments to the ACHDNC 

must be submitted via the registration 

website by 12:00 p.m. ET on Friday, 

February 4, 2022. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Alaina 

Harris at the address and phone number 

listed above at least 10 business days 

prior to the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2022–00896 Filed 1–18–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Publication of the Trusted 

Exchange Framework and Common 

Agreement 

AGENCY: Office of the National 

Coordinator for Health Information 

Technology, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: This notice fulfills an 

obligation under the Public Health 

Service Act (PHSA), which requires the 


jspears on DSK121TN23PROD with NOTICES1